JNJ vs META Stock Comparison: Price, Growth & Valuation (2026)
Use MEXC Stock Compare for a detailed JNJ vs META analysis. Compare JNJ and META across price performance, growth, valuation, profitability and risk, based on market data and the latest reported financials.
JNJ vs META Stock Comparison Summary
JNJ reported year-over-year revenue growth of 8.1%, compared with 27.7% for META. Their P/E ratios are 30.6x and 27.6x, dividend yields are 1.96% and 0.29%, and 30-day volatility levels are 18.8% and 48.3%, respectively. These metrics highlight key differences in growth, valuation, dividend income and market risk. Overall neither stock has a clear lead based on the selected metrics.
Risk Disclaimer: MEXC Stock Compare provides information and comparisons on actual U.S.-listed stocks for reference only. Data may be delayed or inaccurate, does not constitute investment advice, and past performance does not guarantee future results.
JNJ vs META Stock Return Comparison (1W)
Compare the cumulative total returns of Johnson & Johnson (JNJ) and Meta Platforms, Inc. (META) over the selected 1W period. Data as of 2026-09-30 12:00:00.
JNJ vs META Key Equity Metrics Comparison Summary
Johnson & Johnson (JNJ) has a market capitalization of $646.30B and operates in the Health Care sector, with its main business classified under Pharmaceuticals. Its latest quarterly revenue changed +8.1% year over year.
Meta Platforms, Inc. (META) has a market capitalization of $1.62T and operates in the Communication Services sector, with its main business classified under Interactive Media & Services. Its latest quarterly revenue changed +27.7% year over year.
JNJ vs META Key Stock Indicators
| Comparison Metric | JNJ | META | Comparison results |
Stock Price & Returns Latest delayed stock price with 1-day, 1-month and year-to-date returns. | $268.191D: -0.9%1M: -2.3%1Y: +44.6% | $736.501D: -1.7%1M: +25.4%1Y: +0.2% | JNJWin |
Market Capitalization Total market value of the company's outstanding shares. | $646.30B | $1.62T | METAWin |
Sector & Industry The company's market sector and primary industry classification. | Health Care / Pharmaceuticals | Communication Services / Interactive Media & Services | -- |
| Based on delayed market data, JNJ is trading at $268.19, compared with $736.50 for META. Their market capitalizations are $646.30B and $1.62T, respectively. JNJ operates in the Health Care sector, while META belongs to Communication Services. | |||
| JNJ vs META Growth & Profitability | |||
Revenue Growth (YoY) Year-over-year change in revenue. | +8.1% | +27.7% | METAWin |
EPS Growth (YoY) Year-over-year change in earnings per share. | -7.8% | -3.6% | METAWin |
ROIC Return generated from invested capital. | 18.7% | 28.6% | METAWin |
Gross Margin / Operating Margin Profitability before and after operating expenses. | 67.9% / 26.5% | 81.7% / 38.1% | METAWin |
| On growth, JNJ posted revenue growth of +8.1% and TTM EPS growth of -7.8%. META, by comparison, posted revenue growth of +27.7% and TTM EPS growth of -3.6%.On profitability, JNJ recorded a gross margin of 67.9%, an operating margin of 26.5%, and ROIC of 18.7%. For META, the corresponding figures were 81.7%, 38.1%, and 28.6%.Overall, META shows stronger overall growth and profitability. | |||
| JNJ vs META Valuation & Balance Sheet | |||
Free Cash Flow Yield Free cash flow as a percentage of market capitalization. | 3.4% | 2.2% | JNJWin |
Net Debt / EBITDA Net debt relative to EBITDA; a negative value indicates net cash. | 0.8x | 0.2x | METAWin |
Dividend Yield / Payout Ratio Dividend returns relative to share price and the share of earnings paid as dividends. | 1.96% / 59.5% | 0.29% / 7.9% | JNJWin |
| JNJ offers a higher free cash flow yield, indicating a less demanding valuation. META has the stronger balance sheet, while JNJ provides the higher dividend yield. Overall, the two stocks differ mainly in valuation, financial strength and dividend income. | |||
| JNJ vs META Returns & Risk | |||
Total Return (Dividend-Adjusted) Cumulative return over 1, 5 and 10 years, including dividends. | 1Y: +44.6%5Y: +66.1%10Y: +127.0% | 1Y: +0.2%5Y: +5,098.8%10Y: +4,768.7% | METAWin |
30-Day Realized Volatility Annualized volatility based on the past 30 days of daily returns. | 18.8% | 48.3% | JNJWin |
Beta (5Y vs S&P 500) Sensitivity to market movements; above 1 indicates greater market volatility. | 0.16 | 0.97 | JNJWin |
| META has delivered stronger long-term returns, but META also shows higher recent volatility and market sensitivity. | |||
JNJ vs META Valuation & Dividend Metrics
Review JNJ compared with META across valuation, cash flow and dividend metrics, including P/E, forward P/E, free cash flow yield and dividend yield. These figures are provided for reference only and do not represent a fair-value estimate, price target or investment recommendation.
| Metric | JNJ | META | Comparison results |
|---|---|---|---|
Market Cap | $646.30B | $1.62T | METAWin |
P/E (TTM) | 30.6x | 27.6x | METAWin |
P/S | 6.6x | 8.3x | JNJWin |
EV/EBITDA | 19.9x | 17.8x | METAWin |
Dividend Yield | 1.96% | 0.29% | JNJWin |
JNJ vs META Profitability Over Time
Compare JNJ and META across gross margin and operating margin trends over time to understand how each company's profitability has changed. Based on reported financial data only; not a forecast or investment advice.
| TTM | 3Y Avg | 5Y Avg | 10Y Avg | |
|---|---|---|---|---|
| JNJ | 67.9% | 68.6% | 69.1% | 68.1% |
| META | 82.0% | 81.5% | 80.7% | 80.7% |
Technical & Fundamental Stock Analysis
RSI (14, daily)
JNJ 49.53 • META 64.01
Measures short-term price momentum and helps identify possible overbought or oversold conditions.
50/200-DMA Position
JNJ 50D Above / 200D Above • META 50D Above / 200D Above
Shows whether the stock is trading above or below its medium- and long-term trend lines.
R&D % of Revenue
JNJ 15.5% • META 31.4%
Shows how much of revenue is invested in research and development.
Share Count Trend (3Y)
JNJ Decreased • META Decreased
Shows whether the company's share count has increased or decreased over the past three years.
Company Profiles
Johnson & Johnson
Pharmaceuticals
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Meta Platforms, Inc.
Interactive Media & Services
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.
Trade JNJ & META Stock Futures on MEXC
Trade USDT-margined Stock Futures referencing JNJ and META on MEXC, with 24/7 access and leverage of up to 10x. These products are derivatives, do not represent ownership of the underlying shares and involve a significant risk of loss.
Everything You Need to Know About JNJ vs META Stocks
What is MEXC Stock Compare?
MEXC Stock Compare is a side-by-side US stock comparison tool. It helps users compare two companies across stock price performance, market cap, valuation, growth, profitability, balance-sheet strength, dividends and risk. The results are provided for research purposes only and do not constitute investment advice.
Which metrics should I use to evaluate a company's growth?
Start with revenue growth to see how quickly the business is expanding, then review EPS growth to determine whether that growth is translating into higher earnings per share. Gross margin, operating margin and ROIC help assess the quality of that growth by showing profitability and capital efficiency. A company with fast revenue growth but declining margins may be expanding without improving its earnings quality.
How do JNJ and META compare in growth and profitability?
In the latest reported period, JNJ recorded revenue growth of +8.1% and TTM EPS growth of -7.8%, compared with +27.7% and -3.6% for META. META leads on both growth and profitability. This comparison is based on reported financial metrics and does not predict future performance.
What is the difference between P/E (TTM) and Forward P/E?
P/E (TTM) compares the current share price with actual earnings reported over the past 12 months. Forward P/E uses estimated earnings for the next 12 months, so it reflects market expectations but depends on forecasts that may change. Both ratios should be considered alongside growth, profitability and industry peers.
How do the risk profiles of JNJ and META compare?
JNJ has a 30-day realized volatility of 18.8% and a five-year Beta of 0.16, compared with 48.3% and 0.97 for META. META shows higher historical volatility and market sensitivity. These indicators describe historical price movements and market sensitivity, but they do not cover every source of investment risk.
What do dividend yield and payout ratio indicate?
Dividend yield shows the annual dividend relative to the current share price, while the payout ratio shows how much of a company's earnings is distributed as dividends. A higher yield may provide more income, but it can also rise because the share price has fallen. Dividend sustainability should therefore be considered together with earnings, cash flow and the payout ratio.
How should I compare a high-growth stock with a lower-valued stock?
A high-growth stock may trade at a higher valuation if investors expect its revenue and earnings to continue expanding. A lower-valued stock may offer a more conservative entry point, but the lower valuation could also reflect slower growth or higher business risk. Growth, valuation, profitability, cash flow and risk should therefore be considered together.
Which is the better stock, JNJ or META?
There is no single answer for every investor. Growth-focused investors may place greater weight on revenue growth, EPS growth and ROIC, while income-focused investors may prioritize dividend yield and payout sustainability. Investors with lower risk tolerance may focus more on volatility, Beta and balance-sheet strength. MEXC Stock Compare presents the relevant metrics but does not provide a buy or sell recommendation.
Can I trade JNJ and META as RealStocks on MEXC?
Eligible users can trade JNJ and META as real US stocks through MEXC RealStocks if both stocks are currently supported. Users must first open and verify a RealStocks account with MEXC's partner licensed broker. RealStocks represents ownership of actual shares rather than tokenized stock exposure. Availability may vary by stock and region, so users should check the corresponding RealStocks trading page before placing an order.
Disclaimer
The stock prices, financial metrics, comparison results and related information displayed on this page are sourced from third-party providers and are provided for informational and educational purposes only. Data may be delayed, incomplete or inaccurate, and MEXC does not guarantee its accuracy, completeness or timeliness. The comparisons and automated summaries do not constitute financial, investment, legal or tax advice, nor a recommendation to buy, sell or hold any security or financial product. Past performance is not indicative of future results. Users should independently verify the information and assess their own objectives, financial circumstances and risk tolerance before making any decision. Where MEXC stock futures or other derivative products are referenced, such products do not represent ownership of the underlying shares and may involve leverage and a substantial risk of loss. Product availability is subject to applicable laws and regional restrictions.